Pharsight

1. Dapzura Rt patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189	BAXTER HLTHCARE CORP	Daptomycin formulations containing a combination of sorbitol and mannitol	Mar, 2041 (17 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 25 January, 2022

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

DAPZURA RT family patents

2. Nouress patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10653719	September, 2020	Institution Denied	Exela Pharma Sciences LLC	Eton Pharmaceuticals, Inc.
US10583155	June, 2020	Terminated-Denied	Exela Pharma Sciences, LLC	Eton Pharmaceuticals Inc.
US10478453	May, 2020	Institution Denied	Exela Pharma Sciences, LLC	Eton Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478453	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10583155	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10905713	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10933089	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10918662	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10912795	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10653719	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US11510942	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US10905714	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Jan, 2039 (15 years from now)
US11510941	BAXTER HLTHCARE CORP	Stable, highly pure L-cysteine compositions for injection and methods of use	Mar, 2039 (15 years from now)
US10493051	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (15 years from now)
US10543186	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (15 years from now)
US11045438	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (15 years from now)
US10702490	BAXTER HLTHCARE CORP	Cysteine composition and injection	Mar, 2039 (15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need ther...

Dosage: SOLUTION;INTRAVENOUS